Verinurad

Drug Profile

Verinurad

Alternative Names: RDEA-3170

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Ardea Biosciences
  • Developer Ardea Biosciences; AstraZeneca
  • Class Antigouts; Naphthalenes; Propionic acids; Pyridines; Small molecules
  • Mechanism of Action SLC22A12 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gout; Hyperuricaemia

Most Recent Events

  • 01 Aug 2016 Ardea Biosciences completes a phase I trial for Renal impairment in USA (NCT02219516)
  • 03 Jun 2016 AstraZeneca completes licensing agreement with Ironwood Pharmaceuticals
  • 01 Jun 2016 Ardea Biosciences completes a phase IIa trial for Gout (Combination therapy) in USA (NCT02498652)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top